1
|
Schneider J, Sottmann L, Greinacher A, Hagen M, Kasper HU, Kuhnen C, Schlepper S, Schmidt S, Schulz R, Thiele T, Thomas C, Schmeling A. Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med 2021; 135:2335-2345. [PMID: 34591186 PMCID: PMC8482743 DOI: 10.1007/s00414-021-02706-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Accepted: 09/14/2021] [Indexed: 02/06/2023]
Abstract
Thorough postmortem investigations of fatalities following vaccination with coronavirus disease 2019 (COVID-19) vaccines are of great social significance. From 11.03.2021 to 09.06.2021, postmortem investigations of 18 deceased persons who recently received a vaccination against COVID-19 were performed. Vaxzevria was vaccinated in nine, Comirnaty in five, Spikevax in three, and Janssen in one person. In all cases, full autopsies, histopathological examinations, and virological analyses for the severe acute respiratory syndrome coronavirus 2 were carried out. Depending on the case, additional laboratory tests (anaphylaxis diagnostics, VITT [vaccine-induced immune thrombotic thrombocytopenia] diagnostics, glucose metabolism diagnostics) and neuropathological examinations were conducted. In 13 deceased, the cause of death was attributed to preexisting diseases while postmortem investigations did not indicate a causal relationship to the vaccination. In one case after vaccination with Comirnaty, myocarditis was found to be the cause of death. A causal relationship to vaccination was considered possible, but could not be proven beyond doubt. VITT was found in three deceased persons following vaccination with Vaxzevria and one deceased following vaccination with Janssen. Of those four cases with VITT, only one was diagnosed before death. The synopsis of the anamnestic data, the autopsy results, laboratory diagnostic examinations, and histopathological and neuropathological examinations revealed that VITT was the very likely cause of death in only two of the four cases. In the other two cases, no neuropathological correlate of VITT explaining death was found, while possible causes of death emerged that were not necessarily attributable to VITT. The results of our study demonstrate the necessity of postmortem investigations on all fatalities following vaccination with COVID-19 vaccines. In order to identify a possible causal relationship between vaccination and death, in most cases an autopsy and histopathological examinations have to be combined with additional investigations, such as laboratory tests and neuropathological examinations.
Collapse
Affiliation(s)
- Julia Schneider
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Lukas Sottmann
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Andreas Greinacher
- Institute of Immunology and Transfusion Medicine, University Medicine of Greifswald, Greifswald, Germany
| | - Maximilian Hagen
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Hans-Udo Kasper
- Institute of Pathology at Clemens Hospital Münster, Münster, Germany
| | - Cornelius Kuhnen
- Institute of Pathology at Clemens Hospital Münster, Münster, Germany
| | - Stefanie Schlepper
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Sven Schmidt
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Ronald Schulz
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany
| | - Thomas Thiele
- Institute of Immunology and Transfusion Medicine, University Medicine of Greifswald, Greifswald, Germany
| | - Christian Thomas
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Andreas Schmeling
- Institute of Legal Medicine, University Hospital Münster, Münster, Germany.
| |
Collapse
|
2
|
Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med 2021; 385:1680-1689. [PMID: 34379914 PMCID: PMC10662971 DOI: 10.1056/nejmoa2109908] [Citation(s) in RCA: 367] [Impact Index Per Article: 122.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2. Data are lacking on the clinical features of and the prognostic criteria for this disorder. METHODS We conducted a prospective cohort study involving patients with suspected VITT who presented to hospitals in the United Kingdom between March 22 and June 6, 2021. Data were collected with the use of an anonymized electronic form, and cases were identified as definite or probable VITT according to prespecified criteria. Baseline characteristics and clinicopathological features of the patients, risk factors, treatment, and markers of poor prognosis were determined. RESULTS Among 294 patients who were evaluated, we identified 170 definite and 50 probable cases of VITT. All the patients had received the first dose of ChAdOx1 nCoV-19 vaccine and presented 5 to 48 days (median, 14) after vaccination. The age range was 18 to 79 years (median, 48), with no sex preponderance and no identifiable medical risk factors. Overall mortality was 22%. The odds of death increased by a factor of 2.7 (95% confidence interval [CI], 1.4 to 5.2) among patients with cerebral venous sinus thrombosis, by a factor of 1.7 (95% CI, 1.3 to 2.3) for every 50% decrease in the baseline platelet count, by a factor of 1.2 (95% CI, 1.0 to 1.3) for every increase of 10,000 fibrinogen-equivalent units in the baseline d-dimer level, and by a factor of 1.7 (95% CI, 1.1 to 2.5) for every 50% decrease in the baseline fibrinogen level. Multivariate analysis identified the baseline platelet count and the presence of intracranial hemorrhage as being independently associated with death; the observed mortality was 73% among patients with platelet counts below 30,000 per cubic millimeter and intracranial hemorrhage. CONCLUSIONS The high mortality associated with VITT was highest among patients with a low platelet count and intracranial hemorrhage. Treatment remains uncertain, but identification of prognostic markers may help guide effective management. (Funded by the Oxford University Hospitals NHS Foundation Trust.).
Collapse
Affiliation(s)
- Sue Pavord
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Marie Scully
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Beverley J Hunt
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - William Lester
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Catherine Bagot
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Brian Craven
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Alex Rampotas
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Gareth Ambler
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| | - Mike Makris
- From the Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.P., A.R.), the Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-National Institute for Health Research University College London Hospitals-Biomedical Research Centre (M.S., B.C.), the Thrombosis and Haemophilia Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London (B.J.H.), and the Department of Statistical Science, University College London Hospitals NHS Foundation Trust (G.A.), London, the Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), the Department of Haematology, Glasgow Royal Infirmary, Glasgow (C.B.), and the Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield (M.M.) - all in the United Kingdom
| |
Collapse
|
3
|
Ong YC, Chang H, Yeh TS, Kuo MC, Li PL, Wang PN, Lin TL, Wu JH, Hung YS. Impact of Platelet Counts, Surgical Methods, and Preoperative Platelet Transfusion on the Outcome of Splenectomy for Immune Thrombocytopenia. Acta Haematol 2020; 143:465-471. [PMID: 31910413 DOI: 10.1159/000505011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 11/26/2019] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Splenectomy is an important and potentially curative treatment for immune thrombocytopenia (ITP). Laparoscopic splenectomy (LS) has replaced open splenectomy (OS) as the standard approach. The prognostic role of platelet count and the clinical indication of preoperative platelet transfusion are not entirely clear. METHODS We designed a study to explore the prognostic impact of surgical methods, platelet count, and platelet transfusion in a large, single-institute, long-term cohort of ITP patients. RESULT In 118 ITP patients, there was no difference between OS and LS in response and surgical complications. The overall response rate was 77% and the complete response (CR) rate was 70%. Patients with a CR had a trend towards a higher baseline platelet count. A stable platelet count 14-28 days after splenectomy was associated with a sustained long-term response. Patients requiring preoperative platelet transfusion had a lower preoperative platelet count and were more likely to need postoperative transfusion of red blood cells and platelets. They also had a lower postoperative platelet count than the nontransfusion group. Relapse-free survival did not differ. CONCLUSIONS Baseline and postoperative platelet counts are apparently associated with the treatment response to splenectomy but the difference did not reach statistical significance. Preoperative platelet transfusion did not overcome the disadvantage of thrombocytopenia and was not recommended when other preparative measures are available.
Collapse
Affiliation(s)
- Yuen-Chin Ong
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Hung Chang
- School of Medicine, Chang Gung University, Taoyuan, Taiwan,
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan,
- Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan,
| | - Ta-Sen Yeh
- Department of General Surgery,Chang Gung Memorial Hospital, Linkou, Taiwan
| | - Ming-Chung Kuo
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan
| | - Pei-Ling Li
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Po-Nan Wang
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan
| | - Tung-Liang Lin
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan
| | - Jin-Hou Wu
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan
| | - Yu-Shin Hung
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Hematology,Chang Gung Memorial Hospital, Linkou, Taiwan
- Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan
| |
Collapse
|
4
|
Adelborg K, Kristensen NR, Nørgaard M, Bahmanyar S, Ghanima W, Kilpatrick K, Frederiksen H, Ekstrand C, Sørensen HT, Fynbo Christiansen C. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019; 17:912-924. [PMID: 30933417 DOI: 10.1111/jth.14446] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 03/28/2019] [Indexed: 01/27/2023]
Abstract
Essentials Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count. We conducted a cohort study of 3 584 chronic ITP patients from the Nordic countries. Cardiovascular events occurred across all platelet count levels. Cardiovascular or bleeding events were strong prognostic factors for all-cause mortality. Background Among patients with chronic immune thrombocytopenia (cITP), little is known regarding risk factors for cardiovascular and bleeding outcomes and how these events influence mortality. Objectives We examined the rate of cardiovascular events and bleeding requiring a hospital contact according to platelet count levels, as well as the prognostic impact of these events on all-cause mortality in adult patients with cITP. Methods We identified all cITP patients registered in the Nordic Country Patient Registry for Romiplostim during 1996 to 2015. Absolute risks and hazard ratios across platelet count levels based on Cox regression analysis were computed, adjusting for age, sex, prevalent/incident cITP, smoking, and comorbidities. We also compared all-cause mortality rates in cITP patients with and without cardiovascular and bleeding events. Results Among 3 584 cITP patients, 1-year risks were 1.9% for arterial cardiovascular events, 1.2% for venous thromboembolism, and 7.5% for bleeding. Rates of cardiovascular events were similar across platelet counts. Patients with platelet counts <50 × 109 /L had >2-fold higher rates of bleeding than patients with normal platelet counts. These associations were unchanged in time-varying analyses that considered changes in platelet counts during follow-up. Occurrences of cardiovascular and bleeding events were associated with 4-fold to 5-fold increases in 1-year mortality. Conclusions Among patients with cITP, the 1-year risks of cardiovascular events were 1% to 2%, while nearly 8% experienced a bleeding event within 1 year. Cardiovascular events occurred across all platelet levels, while low platelet counts were associated with increased hazards of bleeding. Cardiovascular and bleeding events were strong prognostic factors for mortality.
Collapse
Affiliation(s)
- Kasper Adelborg
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
| | | | - Mette Nørgaard
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
| | - Shahram Bahmanyar
- Clinical Epidemiology Unit & Center for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Waleed Ghanima
- Department of Medicine, Østfold Hospital Trust, Sarpsborg and Department of Hematology, Institute of Clinical Medicine, Oslo University, Oslo, Norway
| | | | - Henrik Frederiksen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
- Department of Hematology, Odense University Hospital, Odense, Denmark
| | - Charlotta Ekstrand
- Clinical Epidemiology Unit & Center for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Henrik T Sørensen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
| | | |
Collapse
|
5
|
Feng FE, Feng R, Wang M, Zhang JM, Jiang H, Jiang Q, Lu J, Liu H, Peng J, Hou M, Shen JL, Wang JW, Xu LP, Liu KY, Huang XJ, Zhang XH. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol 2017; 4:e487-e496. [PMID: 28917657 DOI: 10.1016/s2352-3026(17)30170-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2017] [Revised: 07/31/2017] [Accepted: 08/04/2017] [Indexed: 12/16/2022]
Abstract
BACKGROUND Primary immune thrombocytopenia is a severe bleeding disorder. About 50-85% of patients achieve initial remission from first-line therapies, but optimal second-line treatment remains a challenge. All-trans retinoic acid (ATRA) has an immunomodulatory effect on haemopoiesis, making it a possible treatment option. We aimed to evaluate the efficacy and safety of ATRA plus danazol versus danazol in non-splenectomised patients with corticosteroid-resistant or relapsed primary immune thrombocytopenia. METHODS We did a multicentre, randomised, open-label, phase 2 study of adult patients (≥18 years) with primary immune thrombocytopenia from five different tertiary medical centres in China. Those eligible were non-splenectomised, resistant to corticosteroid treatment or relapsed, and had a platelet count less than 30 × 109 per L. Masked statisticians used simple randomisation to assign patients (1:1) to receive oral ATRA (10 mg twice daily) plus oral danazol (200 mg twice daily) or oral danazol monotherapy (200 mg twice daily) for 16 weeks. Neither clinicians nor patients were masked to group assignments. All patients were assessed every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. The primary endpoint was 12-month sustained response defined as platelet count of 30 × 109 per L or more and at least a doubling of baseline platelet count (partial response), or a platelet count of 100 × 109 per L or more (complete response) and the absence of bleeding without rescue medication at the 12-month follow-up. All randomly allocated patients, except for those who withdrew consent, were included in the modified intention-to-treat population and efficacy assessment, and all patients who received at least one dose of the study agents were included in the safety analysis. Study enrolment was stopped early because the trial results crossed the interim analysis efficacy boundary for sustained response. This trial is registered with ClinicalTrials.gov, number NCT01667263. FINDINGS From June 1, 2012, to July 1, 2016, we screened 130 patients for eligibility; 34 were excluded and 96 were randomly assigned. 93 patients were included in the modified intention-to-treat analysis: 45 in the ATRA plus danazol group and 48 in the danazol group. At the 12-month follow-up, sustained response was achieved more frequently in patients receiving ATRA plus danazol than in those receiving danazol monotherapy (28 [62%] of 45 vs 12 [25%] of 48; odds ratio 4·94, 95% CI 2·03-12·02, p=0·00037). Only two grade 3 adverse events were reported: one (2%) patient receiving ATRA plus danazol with dry skin, and one (2%) patient receiving danazol monotherapy with liver injury. There was no grade 4 or worse adverse event or treatment-related death in either group. INTERPRETATION Patients with primary immune thrombocytopenia given ATRA plus danazol had a rapid and sustained response compared with danazol monotherapy. This finding suggests that ATRA represents a promising candidate for patients with corticosteroid-resistant or relapsed primary immune thrombocytopenia. FUNDING National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Municipal Science and Technology Commission, and the National Key Research and Development Program of China.
Collapse
Affiliation(s)
- Fei-Er Feng
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Ru Feng
- Department of Haematology, Beijing Hospital, National Centre of Gerontology, Beijing, China
| | - Min Wang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Jia-Min Zhang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Hao Jiang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Qian Jiang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Jin Lu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Hui Liu
- Department of Haematology, Beijing Hospital, National Centre of Gerontology, Beijing, China
| | - Jun Peng
- Department of Haematology, Qilu Hospital, Shandong University, Jinan, China
| | - Ming Hou
- Department of Haematology, Qilu Hospital, Shandong University, Jinan, China
| | - Jian-Liang Shen
- Department of Haematology, PLA Navy General Hospital, Beijing, China
| | - Jing-Wen Wang
- Department of Haematology, Beijing Tongren Hospital, Beijing, China
| | - Lan-Ping Xu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Kai-Yan Liu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Xiao-Jun Huang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Xiao-Hui Zhang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Collaborative Innovation Centre of Haematology, Peking University, Beijing, China.
| |
Collapse
|
6
|
Thai LH, Mahévas M, Roudot-Thoraval F, Limal N, Languille L, Dumas G, Khellaf M, Bierling P, Michel M, Godeau B. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore) 2016; 95:e5098. [PMID: 27902585 PMCID: PMC5134764 DOI: 10.1097/md.0000000000005098] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The recent large decrease in splenectomy use for chronic immune thrombocytopenia (ITP) is partly due to still-unsolved questions about long-term safety. We performed the first single-center exposed/unexposed cohort study evaluating the long-term incidence of splenectomy complications in patients with primary ITP. Overall, 83 patients who underwent splenectomy more than 10 years ago (exposed) were matched with 83 nonsplenectomized patients (unexposed) on the date of ITP diagnosis ±5 years, age and gender. After a median follow-up of 192 months (range 0.5-528), 43 patients (52%) achieved overall response after splenectomy. Splenectomized patients experienced more venous thromboembolism (VTE) than controls (n = 13 vs n = 2, P = 0.005). On multivariate analysis, splenectomy was an independent risk factor of VTE (hazard ratio = 4.006, P = 0.032 [95% confidence interval: 1.13-14.21]). Splenectomized patients presented more severe infections on long-term follow-up: all required hospitalization, and 5/26 (19%) infections led to severe sepsis or septic shock and to death for 3 cases (none in controls). However, the incidence of malignancy was similar in both groups, as was cardiovascular risk, which appeared to be related more to ITP than splenectomy. Finally, splenectomy did not significantly decrease overall survival. Despite the risk of thrombosis and severe sepsis, splenectomy remains an effective and curative treatment for ITP.
Collapse
Affiliation(s)
- Lan-Huong Thai
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Matthieu Mahévas
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Françoise Roudot-Thoraval
- Département de Santé Publique, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Nicolas Limal
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Laetitia Languille
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Guillaume Dumas
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Mehdi Khellaf
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Philippe Bierling
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Marc Michel
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| | - Bertrand Godeau
- Centre de Référence des Cytopénies Auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France
| |
Collapse
|
7
|
Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study. Acta Haematol 2016; 135:162-71. [PMID: 26771656 DOI: 10.1159/000442703] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 11/22/2015] [Indexed: 01/19/2023]
Abstract
BACKGROUND Because many physicians seem reluctant to recommend splenectomy for elderly patients with immune thrombocytopenia (ITP), we investigated the safety and efficacy of splenectomy and the predictive factors for response in these patients. METHODS 184 patients with primary ITP were retrospectively analyzed based on age at splenectomy: an elderly group (≥60 years, n = 52) and a younger group (<60 years, n = 132). RESULTS There was no difference in the response rate of elderly versus younger patients (80.7 vs. 80.3%, p = 0.466). Relapse (45.2 vs. 22.6%, p = 0.006), complications, and median postoperative stay (9.5 vs. 7 days, p = 0.019) were significantly higher in the elderly group. The 5-year relapse-free survival of responders was 51.8% in the elderly group and 76.3% in the younger group (p = 0.002). Response to any treatment before splenectomy (HR 2.9, 95% CI: 1.24-6.80, p = 0.014) and platelet count on postoperative day 14 ≥200 × 109/l (HR 31.43, 95% CI: 4.15-238.28, p = 0.001) were independent factors for a favorable response. CONCLUSIONS Age ≥60 years did not influence the response to splenectomy but was associated with increased relapse and postoperative complications. Splenectomy could provide a durable long-term response for elderly ITP patients.
Collapse
Affiliation(s)
- Young Hoon Park
- Department of Internal Medicine at Inha University Hospital, Inha University School of Medicine, Incheon, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sruamsiri R, Dilokthornsakul P, Pratoomsoot C, Chaiyakunapruk N. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding. Pharmacoeconomics 2014; 32:801-813. [PMID: 24849397 DOI: 10.1007/s40273-014-0171-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Although the international guideline recommends intravenous immunoglobulin (IVIG) as the first-line treatment for childhood idiopathic thrombocytopenia purpura (ITP) with life-threatening bleeding, ITP patients may not be able to access IVIG because of the limitation in health benefit packages especially in developing countries. There remains an important policy question as to whether IVIG used as a first-line treatment is worth the money spent. Thus, the objective of this study was to perform a cost-effectiveness analysis of adding IVIG to the standard treatment of platelet transfusion and corticosteroids, for the treatment of childhood ITP with life-threatening bleeding in the context of Thailand. METHODS A cost-effectiveness analysis using a hybrid model consisting of a decision tree and Markov models was conducted with a societal perspective. The effectiveness and utility parameters were determined by systematic reviews, while costs and mortality parameters were determined using a retrospective electronic hospital database analysis. All costs were presented in 2012 US$. The discount rate of 3 % was applied for both costs and outcomes. One-way and probabilistic sensitivity analyses were also performed. RESULTS The incremental cost-effectiveness ratio (ICER) was $3,172 per quality-adjusted life-year gained ($/QALY) for the addition of IVIG versus standard treatment alone. The probability of response to corticosteroids was the most influential parameter on ICER. According to the willingness-to-pay of Thailand, of approximately $3,861/QALY, the probability of IVIG being cost effective was 33 %. CONCLUSIONS The addition of IVIG to standard treatment in the treatment of childhood ITP with life-threatening bleeding is possibly a cost-effective intervention in Thailand. However, our findings were highly sensitive. Policy makers may consider our findings as part of the information for their decision making.
Collapse
MESH Headings
- Child
- Cost-Benefit Analysis
- Decision Trees
- Drug Costs
- Health Care Costs
- Hemorrhage/economics
- Hemorrhage/etiology
- Hemorrhage/mortality
- Hemorrhage/prevention & control
- Hospitalization/economics
- Humans
- Immunoglobulins, Intravenous/economics
- Immunoglobulins, Intravenous/therapeutic use
- Markov Chains
- Models, Economic
- Purpura, Thrombocytopenic, Idiopathic/complications
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/economics
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Quality-Adjusted Life Years
- Severity of Illness Index
- Thailand
Collapse
Affiliation(s)
- Rosarin Sruamsiri
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand
| | | | | | | |
Collapse
|
9
|
Hu MH, Yu YB, Huang YC, Gau JP, Hsiao LT, Liu JH, Chen MH, Chiou TJ, Chen PM, Tzeng CH, Liu CY. Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia. Ann Hematol 2014; 93:1023-9. [PMID: 24441917 DOI: 10.1007/s00277-014-2014-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Accepted: 01/07/2014] [Indexed: 11/25/2022]
Abstract
Patients with immune thrombocytopenia (ITP) may be at increased risk of infection because of the steroids and other immunosuppressive agents used in its treatment. This study aimed to identify events that are associated with infection within 6 months of diagnosis and the impact that infection has on survival. We retrospectively evaluated 239 patients (107 men, 132 women; median age 61 years) diagnosed between January 1997 and August 2011. Every patient received steroid treatment according to the platelet count and the extent of bleeding. Logistic regression analysis was used to identify risk factors associated with the development of infection within 6 months of ITP being diagnosed. Sixty-two patients (25.9 %) developed an infection within 6 months of diagnosis. Multivariate analysis revealed that a lower absolute lymphocyte count (ALC) at diagnosis (<1 × 10(9)/l) was an independent risk factor for infection (P = 0.039; 95 % confidence interval, 1.033-3.599; odds ratio, 1.928). The time to infection event is significant shorter in those of low ALC, compared with those of higher ALC (P = 0.032). Furthermore, the 1-year mortality rate after ITP diagnosis was significantly higher in those patients who developed an infection (P = 0.001). ITP patients with a low absolute lymphocyte count at diagnosis have an increased risk of infection, and those who develop infections have lower 1-year survival.
Collapse
Affiliation(s)
- Ming-Hung Hu
- Division of Haematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Beitou Dist., Taipei City, 11217, Taiwan, Republic of China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Frasier LL, Malani PN, Diehl KM. Splenectomy in older adults: indications and clinical outcomes. Int J Hematol 2013; 97:480-4. [PMID: 23443974 DOI: 10.1007/s12185-013-1300-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2012] [Revised: 01/29/2013] [Accepted: 02/14/2013] [Indexed: 12/01/2022]
Abstract
The aim of this study was to improve the understanding of the indications and associated outcomes among older adults undergoing splenectomy. Data regarding patients of age ≥60 years treated between 1998 and 2008 were reviewed. Fifty patients (age 71.6 ± 8) were identified. Common indications for splenectomy included idiopathic thrombotic purpura (26.0 %) and lymphoma (28.0 %). Patient co-morbidities included hypertension (54 %), coronary artery disease (24 %) and diabetes mellitus (20 %). Twenty-seven patients (54 %) underwent laparoscopic surgery; 23 (46 %) had open procedures; more than half of open splenectomies were conversions from attempted laparoscopy. Mean post-operative length of stay (LOS) was 5.9 ± 5 days (range 1-21). Two patients died in hospital; an additional three died within 6 months. Five patients were discharged to an extended care facility (ECF). Three patients required readmission within 30 days. Increased age was associated with need for ECF (p = 0.01). Increasing LOS, but not age, was associated with 6-month mortality (p = 0.04). Although we noted a 10 % in hospital mortality rate, splenectomy appears to be safe for carefully selected older adults.
Collapse
Affiliation(s)
- Lane L Frasier
- University of Michigan Medical School, Ann Arbor, MI, USA
| | | | | |
Collapse
|
11
|
Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. Am J Hematol 2012; 87:984-7. [PMID: 22729832 DOI: 10.1002/ajh.23275] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2012] [Revised: 04/20/2012] [Accepted: 05/15/2012] [Indexed: 12/17/2022]
Abstract
Patients with ITP may have severe thrombocytopenia, putting them at risk for serious bleeding. ITP trials of new treatments must allow use of standard-of-care therapies to prevent serious bleeding. Thrombopoietin mimetic trials used platelet counts and rescue/concomitant medication use as endpoints. These trials were of insufficient size and duration to measure mortality or serious bleeding, which are infrequent with appropriate treatment. A recent Cochrane review criticized the thrombopoietin mimetic registrational trials for inadequately assessing bleeding and survival. We discuss how these endpoints are difficult to measure in clinical trials designed to improve platelet counts and minimize bleeding, in accordance with ethical trial design.
Collapse
Affiliation(s)
- Ivy Altomare
- Division of Hematology-Oncology, Duke University Medical Center, Durham, NC, USA.
| | | | | |
Collapse
|
12
|
Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012; 87:886-9. [PMID: 22718483 DOI: 10.1002/ajh.23272] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Revised: 05/03/2012] [Accepted: 05/10/2012] [Indexed: 01/16/2023]
Abstract
We report the long-term outcome results of 57 consecutive adult patients with immune thrombocytopenia after being treated with rituximab. According to the different period of therapy, patients received either standard dose (SD) rituximab (i.e., 375 mg/m(2) weekly for 4 weeks) or low dose (LD) rituximab (i.e., 100 mg flat dose weekly for 4 weeks). Overall (OR) and complete response (CR) rates were 60 and 40%, respectively. Patients' median follow-up was 52 months, 82 months in the SD, and 44 months in the LD group; 15 out of 34 responsive patients (44%) relapsed, with median response duration of 24 months (range 3-120). The estimated 4-years event-free survival (EFS, considering events the non response status at month 2 or relapses in responders) was 30%. Patients who received SD vs. LD rituximab had better outcome with regard to short term response (OR 66 vs. 52%, CR 50 vs. 28%), relapse rate (38 vs. 54%), probability to achieve and maintain long-term response (41 vs. 24%) and estimated 4-years EFS (35 vs. 23%). Patients with a longer interval between diagnosis and rituximab therapy had worse EFS [HR = 1.005; 95%IC: (1.002-1.009), P = 0.019]. Three patients developed short-term adverse events, two-serum sickness, and one interstitial pneumonia. Four cases of malignancies and two herpes zoster reactivations were registered during long-term follow-up; one patient died for cerebral bleeding. Rituximab SD appears a safe and active agent allowing in nearly 40% of cases to achieve long-term response and splenectomy sparing effect.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antibodies, Monoclonal, Murine-Derived/therapeutic use
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Follow-Up Studies
- Humans
- Immunologic Factors/administration & dosage
- Immunologic Factors/adverse effects
- Immunologic Factors/therapeutic use
- Middle Aged
- Platelet Count
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/surgery
- Recurrence
- Rituximab
- Salvage Therapy/methods
- Splenectomy
- Young Adult
Collapse
Affiliation(s)
- Francesco Zaja
- Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine, Italy.
| | | | | | | | | | | | | |
Collapse
|
13
|
Bekker E, Rosthøj S. Successful implementation of a watchful waiting strategy for children with immune thrombocytopenia. Dan Med Bull 2011; 58:A4252. [PMID: 21466762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
INTRODUCTION Treatment of newly diagnosed immune thrombocytopenia (ITP) is controversial and guidelines vary internationally. At the Paediatric Department, Aalborg Hospital, a "watchful waiting" approach was adopted in the early 2000s. We aimed to investigate whether this change in strategy had any adverse effects on the subsequent clinical outcomes. MATERIAL AND METHODS Medical records were reviewed for children with ITP presenting with a platelet count < 30 billion/l in the 1990s (n = 22) and in the 2000s (n = 47). Management during the initial admission and events during the first 12 months after diagnosis were recorded. RESULTS The rate of initial treatment with immunoglobulin or steroids was reduced from 64% in the 1990s to 15% in the 2000s. The percentage of children with ITP lasting more than three months did not increase (30% versus 32%). Nor did the occurrence of ITP lasting > 12 months (15% versus 27%). The proportion of children requiring readmission (19% versus 27%) or receiving therapy during follow-up (19% versus 23%) was unchanged. Serious bleeding requiring immediate intervention was equally rare (one episode in the 1990s, two in the 2000s). Cusum plots usefully depicted the changes in management and confirmed that the rate of adverse events did not increase. CONCLUSION A watchful waiting strategy for children with newly diagnosed ITP has been implemented without adverse effects on the duration or the morbidity of ITP.
Collapse
Affiliation(s)
- Emilie Bekker
- Faculty of Health Sciences, University of Aarhus, Denmark.
| | | |
Collapse
|
14
|
Duzhyĭ ID, Shevchenko VP, Shevchenko VV, Grushko AN. [The role of splenectomy in the treatment of idiopatic thrombocytopenic purpura]. Lik Sprava 2011:83-86. [PMID: 22416369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Based on the earlier published data this article describes the role of the spleen in the development of some hematological diseases, the main of which is idiopathic thrombocytopenic purpura (ITP). The authors emphasize the role of splenectomy in the treatment of this disease. At 178 splenectomies performed at the clinic, 23,6 % of operations were carried out for hematological diseases, and among them 42,8 %--for ITP. The authors share their immediate and remote results of the treatment.
Collapse
|
15
|
Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol 2009; 84:631-5. [PMID: 19705429 DOI: 10.1002/ajh.21500] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Immune thrombocytopenic purpura (ITP) is associated with low platelet counts and, consequently, a high risk of adverse events leading to hospitalization. However, there are few data on the clinical and economic burden of hospitalizations for ITP. The Nationwide Inpatient Sample (NIS) database of discharges, a stratified 20% sample of all United States (US) community hospitals across all payers, was used to evaluate discharges in ITP patients. We developed nationally representative numbers of discharges in ITP patients from 2003 to 2006 based on diagnosis codes. Using appropriate weights for each NIS discharge, we created national estimates of average cost, length of stay, and in-hospital mortality for specific groups of ITP-related hospitalizations. Approximately 129,000 discharges occurred between 2003 and 2006 in ITP patients. The average cost associated with all discharges in 2008 dollars was 16,476, with a 6.4-day length of stay and in-hospital mortality of 3.8%. In contrast, the average cost of all hospitalizations in the US population during the same period was 10,039, the average length of stay was 4.8 days, and in-hospital mortality was 2.5%. Mortality risk was higher for ITP patients than for the standard US population adjusted for age and gender, with a relative mortality ratio of 1.5 (95% CI: 1.4-1.6). On the basis of a nationally representative sample of US discharge records from 2003 to 2006, hospitalization with ITP represents an economically and clinically important event. ITP was associated with higher costs, longer stays, and more in-hospital deaths on average than all other hospitalized patients combined.
Collapse
Affiliation(s)
- Mark D Danese
- Outcomes Insights, Inc., Newbury Park, California, USA.
| | | | | | | | | |
Collapse
|
16
|
Markestad T. [Intervention when it's already too late?]. Tidsskr Nor Laegeforen 2008; 128:2618-2619. [PMID: 19023363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
17
|
Hofmann B. [Lack of knowledge about views of knowledge?]. Tidsskr Nor Laegeforen 2008; 128:2617-2618. [PMID: 19023360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
18
|
Fretheim A. [Criticism of Norwegian screening study]. Tidsskr Nor Laegeforen 2008; 128:2617-2618. [PMID: 19023361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
19
|
Doi Y, Yokoyama T, Sakai M. [Trends in mortality from intractable diseases in Japan, 1972-2004]. Nihon Koshu Eisei Zasshi 2007; 54:684-694. [PMID: 18041226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
PURPOSE In 1972, the Ministry of Health, Labour and Welfare of Japan defined intractable diseases as those with unknown etiology, no established treatment regimens, and severe sequelae of physical, mental and social difficulties. Since then, the Ministry has promoted scientific research on these diseases and offered financial support to those suffering from their effects. The purpose of the present study was to analyze trends in deaths from the diseases in Japan over the period from 1972-2004. METHODS For the selected intractable diseases with 100 deaths or more per year, crude (CDR) and direct age-standardized death rates (ADR) were computed using the national underlying-cause-of-death mortality database of Japan based on International Classification of Diseases. Joinpoint regression analysis was applied to identify significant changes in the trends. RESULTS The CDRs in the latest observed year per 1 million persons/year) for males and females were 25.55 and 25.93, respectively, for Parkinson's disease, 5.41 and 6.92 for aplastic anemia, 0.87 and 3.50 for systemic lupus erythematosus, 2.93 and 2.36 for amyloidosis, 1.40 and 1.54 for polyarteritis nodosa, 1.34 and 1.61 for idiopathic thrombocytopenic purpura, and 1.02 and 0.74 for ulcerative colitis. The respective annual percentage changes (APCs) for males and females during the overall period decreased for ulcerative colitis (-5.2% and -7.5%), aplastic anemia (-3.6% and -3.7%), idiopathic thrombocytopenic purpura (-2.1% and -3.0%), and systemic lupus erythematosus (-0.9% and -2.6%), while the APCs increased for amyloidosis (+3.3% and +3.5%), polyarteritis nodosa (+3.2% and +4.0%), and Parkinson's disease (+0.7% in males alone). With the APCs in the latest trend phase, polyarteritis nodosa and Parkinson's disease in females showed appreciable declines; on the other hand, amyloidosis in males demonstrated the significant increase, and ulcerative colitis in males exhibited an apparent leveling off of the decline. CONCLUSION The ADRs for most of the intractable diseases have declined significantly in Japan over the last 3 decades. The decline might be attributed in large part to improved diagnosis and treatment because of the lack of effective primary prevention measures. Support for the affected patients and further research on etiology and radical cure of the diseases must be considered necessary.
Collapse
Affiliation(s)
- Yuriko Doi
- Department of Education, Training Technology and Development, National Institute of Public Health
| | | | | |
Collapse
|
20
|
Ding W, Zent CS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma. Clin Adv Hematol Oncol 2007; 5:257-61. [PMID: 17607284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Autoimmune cytopenia is an important but poorly understood clinical complication of chronic lymphocytic leukemia/ small lymphocytic lymphoma. We review the pathogenesis, clinical presentation, and management of autoimmune hemolytic anemia, immune thrombocytopenia, and pure red blood cell aplasia in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Collapse
MESH Headings
- Agranulocytosis/diagnosis
- Agranulocytosis/etiology
- Agranulocytosis/mortality
- Agranulocytosis/therapy
- Anemia, Hemolytic, Autoimmune/diagnosis
- Anemia, Hemolytic, Autoimmune/etiology
- Anemia, Hemolytic, Autoimmune/mortality
- Anemia, Hemolytic, Autoimmune/therapy
- Diagnosis, Differential
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Male
- Purpura, Thrombocytopenic, Idiopathic/diagnosis
- Purpura, Thrombocytopenic, Idiopathic/etiology
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Red-Cell Aplasia, Pure/diagnosis
- Red-Cell Aplasia, Pure/etiology
- Red-Cell Aplasia, Pure/mortality
- Red-Cell Aplasia, Pure/therapy
Collapse
Affiliation(s)
- Wei Ding
- Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | | |
Collapse
|
21
|
Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol 2006; 81:423-5. [PMID: 16680744 DOI: 10.1002/ajh.20632] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We report our experience with vincristine-loaded platelet infusion in patients with refractory immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome. Ten patients with symptomatic thrombocytopenia and/ or hemolytic anemia who failed to respond to two to six different treatment modalities, including corticosteroids and splenectomy, were treated with infusion of vincristine-loaded platelets. Platelets were harvested by plateletpheresis from a healthy ABO compatible blood donor and incubated with 5 mg vincristine. Excess of vincristine was removed, and platelets were resuspended in 50 ml plasma and infused over 30 min. All 10 patients responded, and 6 of them achieved complete remission. The response was prompt, occurring 3-8 days after vincristine-loaded platelet infusion. Two patients with AIHA are still in remission 9 and 8 years posttreatment with no maintenance treatment. Three ITP patients achieved persisted partial response for 6 years, 5 years, and 11 months; in the remaining 5 patients the response lasted for 2-5 months. No side effects were seen. Our results suggest that this inexpensive and well-tolerated treatment modality may be a useful approach in patients with ITP and AIHA refractory to primary therapy.
Collapse
Affiliation(s)
- Lev Shvidel
- Hematology Institute, Kaplan Medical Center, Rehovot, Israel.
| | | | | | | |
Collapse
|
22
|
Abstract
Immune-mediated heparin-induced thrombocytopenia (HIT) is an uncommon but serious complication of therapy with heparins. It affects all ages and requires replacement of the causative anticoagulant. However, information on alternative antithrombotic use in children with HIT is limited. This paper reviews 27 published and 7 unpublished case reports of children aged 2 weeks to 17 years treated with danaparoid. Thirty-three suffered from HIT or suspected HIT, and 1 child without HIT had a high bleeding risk. All children had severe underlying problems increasing their thrombotic and/or bleeding risk. HIT diagnosis was confirmed serologically or clinically in 26 cases (78.8%). Danaparoid regimens were similar to those used in adults, but in general, younger children needed higher daily doses of danaparoid to achieve the same target plasma anti-Xa levels than teenagers or adults. Of those with a known outcome 28/33 children (84.8%) survived, 7 having suffered from a serious adverse event. Five deaths occurred including 1 thrombotic and 2 major bleeds. Three of the in total 4 major bleeding events occurred in children undergoing surgery with cardiopulmonary bypass. We conclude that despite the reported adverse events danaparoid can be used as an alternative antithrombotic for children who are intolerant of the heparins, except in cases requiring cardiopulmonary bypass surgery.
Collapse
MESH Headings
- Adolescent
- Adult
- Child
- Child, Preschool
- Chondroitin Sulfates/administration & dosage
- Dermatan Sulfate/administration & dosage
- Drug Evaluation
- Fibrinolytic Agents/administration & dosage
- Hemorrhage/blood
- Hemorrhage/drug therapy
- Hemorrhage/mortality
- Heparin/adverse effects
- Heparitin Sulfate/administration & dosage
- Humans
- Infant
- Infant, Newborn
- Male
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/chemically induced
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Risk Factors
- Thrombosis/blood
- Thrombosis/drug therapy
- Thrombosis/mortality
Collapse
Affiliation(s)
- Christoph Bidlingmaier
- Department of Paediatric Haemostaseology, Dr. von Hauner's University Children's Hospital, Munich, Germany.
| | | | | | | |
Collapse
|
23
|
Wang T, Xu M, Ji L, Yang R. Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematol 2006; 115:39-45. [PMID: 16424648 DOI: 10.1159/000089464] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2004] [Accepted: 05/18/2005] [Indexed: 11/19/2022]
Abstract
The management of chronic and refractory idiopathic thrombocytopenic purpura (ITP) in children is controversial. We conducted a retrospective review of our single center experience in China between 1990 and 2003 with splenectomy for chronic ITP in children in order to determine the initial and long-term hematological response, morbidity, mortality, predictors of response to splenectomy and the therapy in children who failed splenectomy. Of 65 children analyzed, the overall immediate clinical response to splenectomy was 89.2%. The median postsplenectomy follow-up time was 52 months (8-124). During follow-up, 9 children (13.8%) relapsed within a median time of 6 months (2-58). The overall morbidity was 1.5% and perioperative mortality was zero. During follow-up, 1 child died of intracranial hemorrhage (ICH) and 1 died of overwhelming postsplenectomy infection (OPSI). The platelet count at day 7 after splenectomy was a predictor of a sustained response to splenectomy but no preoperative parameters were predictors of the response to splenectomy. Of the 15 children who failed splenectomy, excluding the one who died of ICH, only 2 children intermittently required corticosteroids and IVIG. Splenectomy is a potential therapy to provide long-term control of disease in children with chronic ITP and is associated with low morbidity and mortality. The risk of fulminant sepsis remains an omnipresent concern. Antipneumococcal vaccination and antibiotic prophylaxis should be recommended and children should receive timely and adequate antibiotics for bacteria infection to lessen the problem of OPSI.
Collapse
MESH Headings
- Adolescent
- Adrenal Cortex Hormones/therapeutic use
- Anti-Bacterial Agents/therapeutic use
- Child
- Child, Preschool
- Chronic Disease
- Female
- Follow-Up Studies
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Intracranial Hemorrhages/etiology
- Intracranial Hemorrhages/mortality
- Male
- Platelet Count
- Pneumococcal Infections/etiology
- Pneumococcal Infections/mortality
- Pneumococcal Infections/prevention & control
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/complications
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/surgery
- Recurrence
- Retrospective Studies
- Splenectomy
- Vaccination
Collapse
Affiliation(s)
- Tingting Wang
- State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China
| | | | | | | |
Collapse
|
24
|
Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81:19-25. [PMID: 16369979 DOI: 10.1002/ajh.20515] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Refractory disease occurs in 25% or more of adults with idiopathic (immune) thrombocytopenic purpura (ITP). Therapy to elevate the platelet count may be required in a proportion of these patients. Immunosuppressive agents such as prednisone, azathioprine, cyclophosphamide, and cyclosporin have been shown to be effective treatments in a proportion of patients with refractory ITP. A newer immunosuppressive medication, mycophenolate mofetil (MMF), has been used successfully with acceptable toxicity in solid organ transplant patients to reduce the risk of organ rejection. The goal of this study was to determine whether MMF is an effective treatment for refractory ITP. Efficacy, defined as a sustained platelet increase to a level greater than 50 x 10(9)/L, was seen in 7 of 18 patients with refractory ITP. Three of these 7 patients have had intermittent thrombocytopenic episodes while continuing the medication. No severe toxicity was seen, although two of the 18 patients discontinued MMF within the first month of treatment because of side effects, i.e., headache. In summary, MMF may be a useful component of a combination protocol but does not appear to be highly effective as sole therapy in patients with refractory ITP. The data suggests that response rates to MMF may be higher in patients who have had a shorter duration of their ITP.
Collapse
Affiliation(s)
- Drew Provan
- Bart's and The London, Queen Mary's School of Medicine & Dentistry, London, United Kingdom
| | | | | | | |
Collapse
|
25
|
Michel M, Kreidel F, Chapman ES, Zelmanovic D, Bussel JB. Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica 2005; 90:1715-6. [PMID: 16330456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023] Open
Abstract
In this preliminary study, the value of different platelet parameters, measured by the ADVIA120 Analyzer, in predicting the immediate response to intravenous immunoglobulin or intravenous anti-RhoD was assessed in 31 patients with immune thrombocytopenic purpura. The number of large platelets pre-treatment was the only independent predictor of the 24 hour-platelet increase.
Collapse
|
26
|
Abstract
OBJECTIVES The aim of this study was to explore the results of Chinese chronic idiopathic thrombocytopenic purpura (ITP) patients who underwent splenectomy (SE). SUBJECTS AND METHODS Data of 149 chronic ITP patients were retrospectively analyzed. Relapse-free survival was estimated by Kaplan-Meier analysis. Differences between responders and non-responders were evaluated using the chi-square. RESULTS The immediate response rate was 82.6% and the sustained response rate was 63.1%. Twenty-nine patients (19.5%) relapsed during follow-up. The 5-year actuarial relapse-free survival was about 75%. The overall morbidity was 26.1% and mortality was 2.7%. Patients with higher postsplenectomy peak platelet count, shorter time from diagnosis to SE and previous response to IVIG therapy were more likely to have sustained response to SE. CONCLUSION SE is potentially a useful therapy to provide long-term control of disease in adults with chronic ITP and is associated with low morbidity and mortality. Postsplenectomy peak platelet count, time from diagnosis to SE and previous response to intravenous immune globulin therapy appear predictive for response to SE.
Collapse
Affiliation(s)
- Tingting Wang
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
| | | | | | | | | |
Collapse
|
27
|
Gluckman TJ, Segal JB, Fredde NL, Saland KE, Jani JT, Walenga JM, Prechel MM, Citro KM, Zidar DA, Fox E, Schulman SP, Kickler TS, Rade JJ. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol 2005; 95:744-7. [PMID: 15757601 DOI: 10.1016/j.amjcard.2004.11.026] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2004] [Revised: 11/12/2004] [Accepted: 11/12/2004] [Indexed: 10/25/2022]
Abstract
The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.
Collapse
MESH Headings
- Aged
- Angina Pectoris/immunology
- Angina Pectoris/mortality
- Angina Pectoris/therapy
- Angioplasty, Balloon, Coronary
- Antibody Formation/drug effects
- Antibody Formation/immunology
- Coronary Disease/immunology
- Coronary Disease/mortality
- Coronary Disease/therapy
- Female
- Follow-Up Studies
- Heparin/administration & dosage
- Heparin/adverse effects
- Heparin/immunology
- Humans
- Immune Complex Diseases/chemically induced
- Immune Complex Diseases/immunology
- Immune Complex Diseases/mortality
- Male
- Middle Aged
- Myocardial Infarction/immunology
- Myocardial Infarction/mortality
- Myocardial Infarction/therapy
- Platelet Activation/drug effects
- Platelet Activation/immunology
- Platelet Factor 4/immunology
- Purpura, Thrombocytopenic, Idiopathic/chemically induced
- Purpura, Thrombocytopenic, Idiopathic/diagnosis
- Purpura, Thrombocytopenic, Idiopathic/immunology
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Recurrence
- Risk Factors
- Serotonin/blood
- Survival Rate
Collapse
Affiliation(s)
- Tyler J Gluckman
- Department of Medicine Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
We define chronic refractory immune thrombocytopenic purpura (ITP) as ITP with persistent thrombocytopenia following treatment with glucocorticoids and splenectomy. Chronic refractory ITP is uncommon, occurring in fewer than 10% of all adult patients with ITP diagnoses. The goal of treatment is only to achieve a safe platelet count with minimal treatment-related risk. A safe platelet count may be considered to be as low as 10,000/microL, because the risk for major bleeding in otherwise healthy subjects is great only when the platelet count is less than 10,000/microL. Observation without specific treatment is appropriate for patients with moderate thrombocytopenia and no clinically important bleeding symptoms. For patients with chronic refractory ITP who require treatment, there is no consensus for what therapies to use or the sequence in which to use them. For patients with severe and symptomatic thrombocytopenia, the use of anti-CD20 (rituximab) and immunosuppressive agents, alone or in combination, may be most effective. The mechanism of all current therapies is to decrease the accelerated platelet destruction brought about by immunosuppression. An alternative approach, the stimulation of platelet production with thrombopoietic agents, has been successful in investigational studies and may provide a new management option.
Collapse
MESH Headings
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Chronic Disease
- Drug Therapy, Combination
- Hemorrhage/etiology
- Hemorrhage/mortality
- Humans
- Immunosuppressive Agents/therapeutic use
- Prognosis
- Purpura, Thrombocytopenic, Idiopathic/complications
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Rituximab
- Splenectomy
Collapse
Affiliation(s)
- Kiarash Kojouri
- Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
| | | |
Collapse
|
29
|
Abstract
Idiopathic thrombocytopenic purpura (ITP) is a common hematologic disorder manifested by immune-mediated thrombocytopenia. The diagnosis remains one of exclusion, after other thrombocytopenic disorders are ruled out based on history, physical examination, and laboratory evaluation. The goal of treatment is to raise the platelet count into a hemostatically safe range. The disorder is usually chronic, although there is considerable variation in the clinical course and most patients eventually attain safe platelet counts off treatment. However, a subset of patients has severe disease refractory to all treatment modalities, which is associated with considerable morbidity and mortality. This article focuses on the management of primary ITP in adults. We discuss criteria for treatment, the roles of splenectomy and other treatment options along with their side effects, and the management of ITP during pregnancy.
Collapse
MESH Headings
- Adrenal Cortex Hormones/therapeutic use
- Adult
- Aged
- Anti-Inflammatory Agents/therapeutic use
- Antigens, CD20/immunology
- Autoantibodies/blood
- Blood Platelets/immunology
- Female
- Humans
- Immunosuppressive Agents/therapeutic use
- Infant, Newborn
- Male
- Middle Aged
- Platelet Count
- Pregnancy
- Prenatal Diagnosis
- Prognosis
- Purpura, Thrombocytopenic, Idiopathic/diagnosis
- Purpura, Thrombocytopenic, Idiopathic/immunology
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Splenectomy
- Survival Rate
- Treatment Failure
Collapse
Affiliation(s)
- Douglas B Cines
- Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
| | | |
Collapse
|
30
|
Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90:72-7. [PMID: 15642672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by platelet destruction. Glucocorticoids are the first-choice treatment, resulting in a complete (CR) or partial (PR) response in 70-80% of cases. In most cases, however, response is transient or glucocorticoid-dependent. For these and for selected patients with acute refractory ITP, splenectomy may produce a good response (CR+PR) in about 60-80% of cases. We report here the long-term outcome of a large cohort of ITP splenectomized patients. DESIGN AND METHODS We retrospectively analyzed the data on 402 patients (137 males, 265 females) who underwent splenectomy for ITP between 1959 and 2002 in 22 different Hematology Centers. RESULTS Seventy-nine of the 345 (23%) responsive patients relapsed, in most cases (80%) within 48 months from splenectomy. Sixty-eight out of these 79 patients (86%) were then treated with a good response in 46/68 (68%) cases. Fifty-four of the 57 patients refractory to splenectomy and were treated, after the surgery, with a good response in 27/54 (50%) cases. Infection and thrombosis did not significantly weigh upon the outcome of the patients. Only three patients died of hemorrhage during follow-up. By multivariate analysis, the number of therapies before (p<0.01) and higher peak post-splenectomy platelet count (p<0.00001) were predictive of a favorable response to splenectomy, whereas only higher post-splenectomy peak platelet count (p<0.001) was predictive of relapse. INTERPRETATION AND CONCLUSIONS This study shows that splenectomy is a safe procedure and effective in approximately two thirds of patients with chronic ITP. Further studies are required to establish whether surgery-sparing treatments of chronic ITP, such as high-dose dexamethasone, anti-D and anti-CD20 immunoglobulins, have similar or even superior efficacy, risk and cost ratios compared to splenectomy.
Collapse
Affiliation(s)
- Nicola Vianelli
- Hematology and Oncology Institute L. and A. Seràgnoli, University of Bologna.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, Oksenhendler E, Schaeffer A, Bierling P, Godeau B. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004; 83:254-263. [PMID: 15232313 DOI: 10.1097/01.md.0000133624.65946.40] [Citation(s) in RCA: 141] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
To describe the main characteristics and outcome of autoimmune thrombocytopenic purpura (AITP) in patients with common variable immunodeficiency (CVID), we analyzed data from 21 patients and reviewed additional cases from the literature. To be included in this study, patients had to have CVID and a previous history of AITP with a platelet count < or = 50 x 10(9)/L at onset. A complete response to treatment was defined by a platelet count > or = 150 x 10(9)/L, and a partial response by a platelet count >>50 x 10(9)/L with an increase of at least twofold the initial level. The median platelet count at AITP diagnosis was 20 x 10(9)/L (range, 2-50 x 10(9)/L). The median age at AITP diagnosis was 23 years (range, 1-51 yr), whereas the median age at CVID diagnosis was 27 years (range, 10-74 yr). CVID was diagnosed before the onset of AITP in only 4 patients (19%), 3 of whom were being treated with intravenous immunoglobulin (i.v.Ig) replacement therapy. CVID was diagnosed more than 6 months after AITP in 13 cases (62%), and the 2 conditions were diagnosed concomitantly in 4 cases. Eleven patients (52%) had at least 1 autoimmune manifestation other than AITP, among which autoimmune hemolytic anemia (7 cases) and autoimmune neutropenia (5 cases) were preeminent. Seventeen of the 21 patients (80%) received at least 1 treatment for AITP; 13 patients received corticosteroids alone and 7 (54%) achieved at least a partial response; 8 patients received i.v.Ig at 1-2 g/kg alone or in combination with steroids, leading to a short-term response rate of 50%. Four patients underwent a splenectomy (2 complete responses, 2 failures); 2 additional splenectomies were performed for associated autoimmune hemolytic anemia. With a mean follow-up of 5.6 years after the surgical procedure, none of the 6 splenectomized patients had a life-threatening infection. With a median follow-up after AITP onset of 12 years, 13/21 patients (62%) were in treatment-free remission (7 complete responses, 6 partial responses), 7 patients (23%) were in remission while on prednisone < or = 20 mg/day with or without azathioprine, and only 1 patient still had a platelet count <50 x 10(9)/L. Five patients had died at the time of the analysis; none of the deaths was related to a hemorrhage. Severe infections including 3 fatal bacterial infections and 2 opportunistic infections occurred in 6 patients during or after treatment of AITP. In conclusion, AITP, alone or in combination with autoimmune hemolytic anemia (Evans syndrome) and/or autoimmune neutropenia, is frequent in patients with CVID, and is not prevented by i.v.Ig substitutive therapy. Since AITP frequently precedes the diagnosis of CVID, testing for immunoglobulin levels should be performed in every patient diagnosed with AITP. Steroids and splenectomy seem to have the same efficacy as in idiopathic AITP, but the increased risk of severe infections must be taken into consideration.
Collapse
Affiliation(s)
- Marc Michel
- From Departments of Internal Medicine (MM, VC, AS, BG) and Immunology (YL), and Etablissement Français du Sang (OH, PB), Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris, Créteil; Department of Immuno-Hematology (LG, EO), Hôpital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris; Department of Internal Medicine (MR), Hôspital Hotel Dieu, Clermont-Ferrand; and Department of Hematology (YL), Hôpital Necker, Assistance Publique-Hopitaux de Paris, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Maloisel F, Andrès E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116:590-4. [PMID: 15093754 DOI: 10.1016/j.amjmed.2003.12.024] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2002] [Revised: 09/29/2003] [Accepted: 09/29/2003] [Indexed: 11/19/2022]
Abstract
BACKGROUND Adults with chronic idiopathic thrombocytopenic purpura (ITP) in whom standard-dose corticosteroids and splenectomy have failed or who have contraindications to these therapies often require further treatment for life-threatening thrombocytopenia or bleeding. We studied whether danazol, an attenuated androgen, is useful in this setting. METHODS To assess both clinical outcome and tolerance issues, 57 patients who had refractory chronic ITP (n = 27) or who had contraindications to splenectomy or corticosteroids or who refused these therapeutic options (n = 30) were studied. RESULTS Thirty-eight patients experienced a partial or complete response to therapy (67%), among whom 27 (46%) remained in remission at a median (+/- SD) of 119 +/- 45 months. Treatment tolerance was acceptable, although severe adverse events were reported in 9 patients (16%). CONCLUSION Our findings suggest that danazol therapy may be beneficial in the management of refractory chronic ITP or when there are contraindications to splenectomy or corticosteroids (or both).
Collapse
|
33
|
Affiliation(s)
- John Lilleyman
- Department of Paediatric Haematology and Oncology, Barts and The London, Queen Mary's School of Medicine and Dentistry, The Royal London Hospital, Whitechapel, London, UK.
| |
Collapse
|
34
|
El-Alfy MS, El-Tawil MM, Shahein N. 5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children. Acta Haematol 2003; 110:20-4. [PMID: 12975552 DOI: 10.1159/000072409] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2002] [Accepted: 03/25/2003] [Indexed: 11/19/2022]
Abstract
UNLABELLED The long-term outcome after splenectomy in children with chronic immune thrombocytopenic purpura (ITP) has not been widely analyzed. We reviewed the medical records of 288 children and adolescents with chronic ITP between 1980 and 1996: 112 were splenectomized; 59 were steroid resistant and 42 were steroid dependent, and 11 were managed with repeated courses of intravenous immunoglobulin (IVIG). All had platelet counts (PCs) <30 x 10(9)/l with frequent bleeding episodes or persistent thrombocytopenia <10 x 10(9)/l. Ninety-eight patients (88%) were evaluated; 58 (60%) patients had never received immunotherapy for ITP following splenectomy. At 5 years, 44 (45%) remained in complete response (CR) and 34 (35%) in partial response (PR). In multivariate analysis, steroid-resistant patients were more likely to relapse after an initial CR (RR 5.2). CONCLUSION The long-term CR was 45%; 60% had stable PCs >30 x 10(9)/l not requiring therapy. Most postsplenectomy relapses occurred during the 1st year. Initial response to steroids and IVIG prior to splenectomy was a predictor of long-term response to splenectomy.
Collapse
Affiliation(s)
- Mohsen S El-Alfy
- Hematology-Oncology Clinic, Children's Hospital, Ain Shams University, Cairo, Egypt.
| | | | | |
Collapse
|
35
|
Rossi G, Cattaneo C, Motta M, Pizzocaro C, Lanzi S, Pouchè A. Platelet kinetic study in patients with idiopathic thrombocytopenic purpura (ITP) refractory or relapsing after corticosteroid treatment. Hematol J 2003; 3:148-52. [PMID: 12111651 DOI: 10.1038/sj.thj.6200170] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2002] [Accepted: 05/07/2002] [Indexed: 11/09/2022]
Abstract
BACKGROUND A platelet kinetic study (PKS) is not indicated in the evaluation of adult patients with idiopathic thrombocytopenic purpura (ITP) at presentation. However, in ITP patients refractory to or relapsing after corticosteroid therapy, its appropriateness is considered uncertain. METHODS We prospectively performed a PKS with (111)In oxine-labeled autologous platelets in 93 consecutive adult ITP patients failing steroid treatment. RESULTS In 22 patients (24%) a primary condition accounting for thrombocytopenia was identified (17 with myelodysplastic syndrome and three aplastic anemia). Non-ITP patients had significantly longer platelet circulating life span (P=0.0001), lower splenic platelet uptake (P=0.008) and higher liver platelet uptake (P=0.05) compared to 71 patients with confirmed ITP. Among ITP patients with platelets persistently <50 x 10(9)/L, splenectomy was considered in 48 cases. In 23 (48%) it was prospectively excluded because of platelet life span > or = 7 days (11 cases), no splenic platelet uptake together with high liver uptake (10 cases), or both conditions (two cases). Splenectomy was successfully carried out in the other 25 patients, obtaining a response rate of 100% (22 complete responses; three partial responses). Persistent relapse occurred in six of 25 (24%) splenectomized patients after a median of three months (range 1-8). PKS parameters were not able to predict post-splenectomy relapse, although relapsed patients had lower splenic/hepatic platelet uptake ratio (2.6 in relapsed vs 4.9 in persistently responsive patients; P=0.08). CONCLUSIONS It was concluded that in patients with chronic ITP failing steroid therapy, some PKS parameters may be prospectively used to increase the short term success rate of splenectomy.
Collapse
Affiliation(s)
- Giuseppe Rossi
- Sezione di Ematologia, Spedali Civili, Università di Brescia, Brescia, Italy.
| | | | | | | | | | | |
Collapse
|
36
|
Omine M. [Epidemiology and long-term prognosis of ITP]. Nihon Rinsho 2003; 61:655-63. [PMID: 12718092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
Research Committee for ITP was organized in 1972 under the support of the Government and since then efforts have been concentrated to elucidate pathophysiology of the disease and to establish better management of patients with ITP. A nation-wide epidemiological survey was conducted with estimates for prevalence of 7,500-10,500(5.5-11.5/100,000 population), with annual incidence of 1,700-4,100. Repeated survey after 10 years gave similar values for both parameters. Effectiveness of various treatments including standard modality and other special approaches was evaluated by multicenter collaborative studies, and long-term clinical course and outcome were analyzed to better understand the natural history of ITP. Our insufficient understanding regarding true natural history of ITP was discussed as a problem for the future investigation.
Collapse
|
37
|
Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72:94-8. [PMID: 12555211 DOI: 10.1002/ajh.10253] [Citation(s) in RCA: 116] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Splenectomy is the only treatment of ITP known to have "curative" effects in a substantial fraction of patients. However, the true long-term outcome is uncertain and controversial because published series have not adjusted for the duration of follow-up. This IRB-approved retrospective study included all patients with ITP who underwent splenectomy between 1988-1993 at three major medical centers and required a minimum postoperative 5-year follow-up. Complete response (CR) was defined as all postsplenectomy platelet counts >150 x 10(9)/L without treatment; partial response (PR) as platelet counts > or =50 x 10(9)/L without treatment; and failure as platelet counts <50 x 10(9)/L or receiving therapy after splenectomy. Seventy-five patients identified with ITP underwent splenectomy from 1988 to 1993. Three patients died prior to 5-year follow-up, and 56 of the 72 patients (78%) were evaluable with follow-up for five years or longer, median 7.5 years. The immediate postoperative complete remission rate was 77%; 57% of patients have remained in prolonged CR. Thirty-seven patients (66%) have not required any therapy after splenectomy. Eight patients had platelet counts >150 x 10(9)/L for 4-8.5 years before relapsing; no clear plateau was attained in the remission curve. There was no operative mortality. Ten patients (18%) reported minor postoperative bleeding episodes. No life-threatening infections, significant heart disease, or pulmonary hypertension developed after splenectomy in the 434 patient-years of follow-up. This study helps to define the long-term results of splenectomy for ITP.
Collapse
Affiliation(s)
- Joseph Schwartz
- Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
| | | | | | | | | | | |
Collapse
|
38
|
Sailer T, Weltermann A, Zoghlami C, Kyrle PA, Lechner K, Pabinger I. Mortality in severe, non aggressively treated adult autoimmune thrombocytopenia. ACTA ACUST UNITED AC 2003; 4:366-9. [PMID: 14502264 DOI: 10.1038/sj.thj.6200299] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A total of 130 consecutive patients with severe autoimmune thrombocytopenia (AITP) who were diagnosed and treated in our institution between 1991 and 2001 were followed up. The patients were almost exclusively treated with prednisolone, immunoglobulin and/or splenectomy. The aim of the treatment was to keep the platelet count at least above 10,000 microL. None of the patients died from bleeding, two patients died from infection and seven from other unrelated causes. These data show that AITP is a relatively benign disease that does not require aggressive treatment. Bleeding can be prevented if the platelet count can be kept above 10,000 microL.
Collapse
Affiliation(s)
- Thomas Sailer
- Department of Medicine I, Division of Hematology and Blood Coagulation, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|
39
|
D'Orazio AI, Fisher MD. 43rd Annual Meeting of the American Society of Hematology, December 7-11, 2001, Orlando, Florida. Clin Lymphoma 2002; 2:205-8. [PMID: 11970758 DOI: 10.1016/s1526-9655(11)70230-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
MESH Headings
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Burkitt Lymphoma/drug therapy
- Burkitt Lymphoma/mortality
- Burkitt Lymphoma/pathology
- Child
- Child, Preschool
- Clinical Trials, Phase II as Topic
- Congresses as Topic
- Female
- Humans
- Lymphoma, T-Cell/drug therapy
- Lymphoma, T-Cell/mortality
- Lymphoma, T-Cell/pathology
- Male
- Middle Aged
- Prognosis
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/pathology
- Randomized Controlled Trials as Topic
- Risk Assessment
- Severity of Illness Index
- Societies, Medical
- Survival Rate
- Treatment Outcome
Collapse
|
40
|
|
41
|
Abstract
To study outcomes of adults with idiopathic thrombocytopenic purpura (ITP), we performed a follow-up study in a cohort of 152 consecutive patients who were treated according to a well-defined algorithm. Long-term outcomes were determined relative to the response 2 years after diagnosis, because most (93%) patients who ultimately attained platelet counts above 30.0 x 10(9)/L (30 000/microL) did so within this time frame. Complete follow-up for mortality could be studied in 99% of patients and for morbidity in 95% of patients, with a mean of 10.5 years. Within 2 years after diagnosis, 4 patients died, 2 were lost to follow-up, and 12 were reclassified as having secondary immune thrombocytopenia. Of the remaining 134 patients, 114 (85%) had obtained platelet counts above 30.0 x 10(9)/L while all therapies had been discontinued. These patients had a long-term mortality risk equal to the general population. Twelve of 134 patients (9%), all with severe thrombocytopenia, had refractory disease and suffered a mortality risk of 4.2 (95% confidence interval, 1.7-10.0). Bleeding and infection equally contributed to the death of these patients. Another 8 patients (6%) had platelet counts above 30.0 x 10(9)/L while on maintenance therapy. Similar to patients with refractory disease, these latter patients had considerably increased ITP-related hospital admissions, but mortality was only slightly higher than in the general population. In conclusion, most adults with ITP have a good outcome with infrequent hospital admissions and no excess mortality. The absence of gross morbidity and mortality in patients with moderate thrombocytopenia supports clinical practice refraining from further treatment.
Collapse
Affiliation(s)
- J E Portielje
- Departments of Internal Medicine, Clinical Epidemiology, and Hematology, Leiden University Medical Center, The Netherlands.
| | | | | | | |
Collapse
|
42
|
Vianelli N, Valdrè L, Fiacchini M, de Vivo A, Gugliotta L, Catani L, Lemoli RM, Poli M, Tura S. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 2001; 86:504-9. [PMID: 11410414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Idiopathic thrombocytopenic purpura (ITP) induces thrombocytopenia by means of an autoimmune mechanism. Despite the available therapies a subset of patients develop chronic refractory severe thrombocytopenia (i.e. a platelet count consistently lower than 20 to 30x10(9)/L), and life-threatening bleeding can occasionally occur. It has been suggested that the risk of major bleeding is higher in elderly patients and in patients with bleeding at diagnosis. However, since clear data on the influence of clinical and/or laboratory parameters on outcome are lacking, some patients may be receiving unnecessary treatment. DESIGN AND METHODS We made a retrospective analysis of a series of 310 patients with chronic ITP (108 males and 202 females), with a median age at diagnosis of 40 years (range 8-87 years). The median follow-up time was 121 months, (range 7-434 months). Therapy was most often started in the presence of hemorrhagic complications and/or a platelet count <30x10(9)/L either at diagnosis or during follow-up. RESULTS Our findings confirmed that patients who were symptomatic at diagnosis were more likely to have bleeding during their follow-up. Moreover, all the patients who suffered major bleeding during their follow-up had median platelet counts of 10x10(9)/L (range 1-20) at that time. Only one patient, aged 43 years, died of hemorrhage following prolonged severe thrombocytopenia. Age >60 years was not associated with any significant differences in incidence of bleeding at diagnosis or during follow-up. INTERPRETATION AND CONCLUSIONS We conclude that prospective studies are required to evaluate whether it may be reasonable to treat only symptomatic patients, independently of age.
Collapse
Affiliation(s)
- N Vianelli
- Istituto di Ematologia e Oncologia Medica Seràgnoli, Policlinico S. Orsola, via Massarenti 9, 40138 Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Winde G, Schmid KW, Lügering N, Fischer R, Brandt B, Berns T, Bünte H. Results and prognostic factors of splenectomy in idiopathic thrombocytopenic purpura. J Am Coll Surg 1996; 183:565-74. [PMID: 8957458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Splenectomy is the therapy of choice after relapse following different immunosuppressive treatments for idiopathic thrombocytopenic purpura, which is still the most frequent cause of thrombocytopenia. STUDY DESIGN A prospective clinical study was undertaken to evaluate the rate of complete remission in idiopathic thrombocytopenic purpura after splenectomy, to reveal the influence of preoperative immunosuppression on the postoperative course in groups of patients with different responses to treatment, and to describe possible prognostic factors predicting the postoperative course of idiopathic thrombocytopenic purpura. Difino's classification of remission was used. After fulfilling criteria for admission into the study, 72 patients who had undergone splenectomy (male to female ratio, 1:1.4) were examined. RESULTS Early postoperative mortality and morbidity rates were 3 percent each. The following degrees of remission were achieved: complete remission, 72 percent; partial remission, 15 percent; partial remission affording further medical support, 6 percent; and no remission, 4 percent. Platelet counts differed significantly between complete and partial remission, but not between patients who did or did not experience a response to different preoperative medical strategies (Tukey-Kramer test, p < .05; t test, not significant). The correlation of megakaryocytopoiesis and the site of thrombocytolysis to the stages of remission was significant (Fisher's exact test). Patients with hyperplasia of splenic follicles had significantly higher platelet counts 2 years after operation than did those without hyperplastic splenic follicles (Student-Newman-Keuls test). CONCLUSIONS Splenectomy is a low morbidity and low mortality procedure. It is, therefore, a treatment of choice after relapse following immunosuppressive courses. Isolated splenic thrombocytolysis and hyperplasia of megakaryocytopoiesis and of splenic follicles correlated with better postoperative outcome (ie, stable remission and platelet counts) and could serve as possible prognostic factors for the postoperative course in idiopathic thrombocytopenic purpura.
Collapse
Affiliation(s)
- G Winde
- Department of General Surgery, Westfälische Wilhelms-University of Muenster, Germany
| | | | | | | | | | | | | |
Collapse
|
44
|
Centurioni R, Bobbio-Pallavicini E, Porta C, Rodeghiero F, Gugliotta L, Billio A, Tacconi F, Ascari E. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. Haematologica 1995; 80:325-31. [PMID: 7590501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG). METHODS We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities. RESULTS Of the 17 patients, 7 died from disease progression (41.1%), 2 achieved partial remission (11.7%) and the remaining 8 achieved complete remission (47%). Of the 10 cases (58.8%) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed. CONCLUSIONS Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.
Collapse
Affiliation(s)
- R Centurioni
- Ospedale Nuovo di Torrette, Università di Ancona, Italy
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA. Energy restriction prevents and reverses immune thrombocytopenic purpura (ITP) and increases life span of ITP-prone (NZW x BXSB) F1 mice. J Nutr 1994; 124:2016-23. [PMID: 7931711 DOI: 10.1093/jn/124.10.2016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Male (NZW x BXSB)F1 (W/BF1) mice develop immune thrombocytopenic purpura (ITP), which involves antiplatelet autoantibodies and shortened platelet life span. To determine whether reduction of dietary energy can prevent the development or reverse the progression of ITP, male W/BF1 mice were separated into five experimental groups and either given free access to semipurified diet (designated Group A, n = 50) or consumed 32% less energy from an otherwise comparable diet (Group B6, n = 20), or were initially allowed free access to diet then switched to energy restriction at ages 14, 17 or 22 wk (Groups B14, n = 10; B17, n = 20; B22, n = 20). Thrombocytopenia was prevented by energy restriction in Group B6 mice. Platelet-associated IgG (PAIgG) autoantibody levels and the number of splenic antiplatelet antibody-forming cells were low (P < 0.01) and the survival of injected IgG-coated RBC was extended in energy-restricted Group B6 mice (P < 0.01) compared with mice in Group A. Group A mice became progressively thrombocytopenic, with platelet counts as low as 34 x 10(10)/L. Progression of thrombocytopenia was reversed when energy restriction was initiated in Groups B14, B17 and B22, with platelet counts > or = 88 x 10(10)/L and reduction of PAIgG. Life span was extended among early onset energy-restricted Group B6 and Group B14 mice (P = 0.0001 and P = 0.005) but not among late onset energy-restricted Group B17 and Group B22 mice (P = 0.06 and P = 0.35) compared with Group A mice.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H Mizutani
- Department of Pediatrics, University of South Florida, All Children's Hospital, St. Petersburg 33701
| | | | | | | | | |
Collapse
|
46
|
Abstract
ITP (immune thrombocytopenic purpura) is generally considered a benign disease. Despite what may be severe thrombocytopenia, most patients with ITP do not suffer significant bleeding episodes. Mortality is rare, and the majority of cases are managed successfully with conventional treatments. For patients who maintain a platelet count of > 20,000/microliters, aggressive immunosuppressive therapy is usually unwarranted. There are some patients with ITP who are at increased risk of serious morbidity and mortality from their disease. Fatal cases of ITP are rarely mentioned in published reports. In this study we review the incidence of mortality and describe the deaths of seven patients with ITP, with the aim of identifying and improving management of high-risk cases. Based on our review of the literature and analysis of cases at our institution, fatal cases of ITP fall into three groups: death from intracranial hemorrhage with severe thrombocytopenia, death after splenectomy, and death due to infection after cytotoxic treatments. Patients who appear to carry increased risk include: 1) older patients; 2) chronic, refractory patients with a history of hemorrhage; and 3) patients with concomitant bleeding diatheses such as uremia and hemophilia.
Collapse
Affiliation(s)
- E Schattner
- Department of Medicine, New York Hospital-Cornell Medical Center, New York 10021
| | | |
Collapse
|
47
|
Naouri A, Feghali B, Chabal J, Boulez J, Dechavanne M, Viala JJ, Tissot E. Results of splenectomy for idiopathic thrombocytopenic purpura. Review of 72 cases. Acta Haematol 1993; 89:200-3. [PMID: 8213001 DOI: 10.1159/000204523] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Seventy-two patients underwent splenectomy for idiopathic thrombocytopenic purpura between 1979 and 1990. Mean age at splenectomy was 36.4 years (range 11-73). Indications for splenectomy were corticodependence in 21 cases and resistance to steroids in 44 cases. Thirty-five patients had platelet kinetic studies by 51Cr alloplatelets; 22 of them had splenic sequestration. Hematologic results were evaluated on discharge, at 3 months and in the long term (median follow-up 5.4 years). We had no mortality, morbidity was seen in 7% of the cases. None of the patients suffered from secondary infectious complications. 89% had good results on discharge (> 120 x 10(9)/l), 72.6% at 3 months and 90% on long-term follow-up. Factors associated with good response to splenectomy included a high postoperative platelet count (more than 120 x 10(9)/l on discharge), younger age at the time of surgery, preoperative corticodependence and predominantly splenic sequestration.
Collapse
Affiliation(s)
- A Naouri
- Department of General and Digestive Surgery, Edouard Herriot Hospital, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
48
|
Dan K, Gomi S, Kuramoto A, Maekawa T, Nomura T. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Int J Hematol 1992; 55:287-92. [PMID: 1498319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura (ITP) was conducted by the Idiopathic Disorders of Hematopoietic Organs Research Committee (IDHORC), the Ministry of Health and Welfare of Japan. The aim of the study was to establish an improved therapeutic guide for chronic ITP. Of the 247 eligible patients 175 have been followed up to the present time, 16 patients have died, and 56 have been lost to follow-up. The median follow-up time was 55 months (range: 1 to 91 months). Of the 206 patients treated with corticosteroids, 13.1% achieved sustained complete remission. Splenectomy produced remissions in 52.5% of 72 patients evaluated 12 months after operation. Eighty-five patients were treated with immunosuppressive agents, but the response rates were low and the effect was transient in most cases. In the patients followed up without any specific treatment, the mean platelet counts showed slight improvement. Of the 16 patients who died during the observation period, only one died of bleeding; the remaining 15 died of causes unrelated to thrombocytopenia. It is noteworthy that five patients who were treated with corticosteroids or immunosuppressive agents died of infection.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Algorithms
- Child
- Child, Preschool
- Chronic Disease
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Hemorrhagic Disorders/etiology
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Immunosuppressive Agents/therapeutic use
- Infant
- Male
- Middle Aged
- Platelet Count
- Prednisolone/therapeutic use
- Prospective Studies
- Purpura, Thrombocytopenic, Idiopathic/complications
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/surgery
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Remission Induction
- Splenectomy
- Survival Analysis
Collapse
Affiliation(s)
- K Dan
- Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
| | | | | | | | | |
Collapse
|
49
|
Taillan B, Hastier P, Ferrari E, Fuzibet JG, Gratecos N, Vinti H, Pesce A, Dujardin P. [Idiopathic thrombocytopenic purpura in elderly subjects]. Presse Med 1991; 20:1651-4. [PMID: 1836567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
During an 8-year period, 35 patients aged over 60 and presenting with idiopathic thrombocytopenic purpura were observed. At the time of diagnosis, 51.5 percent had haemorrhages which were major in 26 percent of the cases. Response to various treatments, notably corticosteroid therapy, was weak (43 percent). During the course of the disease, 2 patients (5.7 percent) died of cerebral haemorrhage. This series confirms the importance of haemorrhagic syndrome and the resistance to treatment of the elderly as opposed to younger subjects. This is probably due to the heterogeneity of purpura in old age: in a number of patients purpura corresponded to refractory chronic thrombocytopenia or to chronic thrombocytopenia associated with carcinoma.
Collapse
MESH Headings
- Adrenal Cortex Hormones/therapeutic use
- Age Factors
- Aged
- Aged, 80 and over
- Androgens/therapeutic use
- Cerebral Hemorrhage/etiology
- Female
- Humans
- Immunization, Passive
- Immunosuppressive Agents/therapeutic use
- Male
- Middle Aged
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/complications
- Purpura, Thrombocytopenic, Idiopathic/mortality
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Recurrence
- Retrospective Studies
- Splenectomy
Collapse
Affiliation(s)
- B Taillan
- Service de Médecine Interne I-Hématologie, Hôpital de Cimiez, Nice
| | | | | | | | | | | | | | | |
Collapse
|